Refludan lepirudin direct thrombin inhibitor: Phase III data; marketed to treat heparin-induced thrombocytopenia

Hoechst Marion Roussel presented results from its 10,141-patient OASIS-2 study comparing a 72-hour infusion

Read the full 146 word article

How to gain access

Continue reading with a
two-week free trial.